Ology

INSIGHTEC NAMED BIOFLORIDA COMPANY OF THE YEAR

Retrieved on: 
Monday, October 16, 2023

MIAMI, Oct. 16, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida's life sciences industry. The award was presented at BioFlorida's 26th Annual Conference in Ponte Verdra Beach to an audience of statewide leaders in Florida's life sciences industry.

Key Points: 
  • MIAMI, Oct. 16, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida's life sciences industry.
  • The David J. Gury Company of the Year Award, named for one of the founding directors of BioFlorida, honors a company that has significant company achievements with measurable results including financing deals, partnering agreements, research discoveries, grants, clinical trials, approvals, product development and commercialization milestones.
  • Recipients must also be BioFlorida members who demonstrate a history of service to BioFlorida and its mission - to advance the life sciences industry in Florida.
  • Insightec is also exploring other treatment applications in the body, such as prostate disease.

Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment

Retrieved on: 
Wednesday, February 9, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220209005461/en/
    Resilience's site in Alachua, Florida, will develop a monoclonal antibody as a medical countermeasure to botulinum neurotoxins for the US Department of Defense.
  • We are proud to support the Department of Defense develop this important medicine to protect the warfighter from exposure to botulinum toxins, said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.
  • The contract was awarded by the DODs Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense ( JPEO-CBRND ).
  • Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.

Three healthcare providers in the Netherlands order joint digital pathology solution from Sectra

Retrieved on: 
Thursday, July 15, 2021

LINKPING, Sweden and ALMERE, The Netherlands, July 15, 2021 /PRNewswire/--International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received an order from three healthcare providers in the Netherlands for a joint digital pathology solution.

Key Points: 
  • LINKPING, Sweden and ALMERE, The Netherlands, July 15, 2021 /PRNewswire/--International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received an order from three healthcare providers in the Netherlands for a joint digital pathology solution.
  • I am so proud to be part of this journey," says Sectra Benelux Account Manager Digital Pathology, Jeroen van Laarhoven.
  • Sectra's digital pathology solution will be integrated with the laboratory information systems (LIS) used at the different locations.
  • The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise.

Three healthcare providers in the Netherlands order joint digital pathology solution from Sectra

Retrieved on: 
Thursday, July 15, 2021

LINKPING, Sweden and ALMERE, The Netherlands, July 15, 2021 /PRNewswire/--International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received an order from three healthcare providers in the Netherlands for a joint digital pathology solution.

Key Points: 
  • LINKPING, Sweden and ALMERE, The Netherlands, July 15, 2021 /PRNewswire/--International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received an order from three healthcare providers in the Netherlands for a joint digital pathology solution.
  • I am so proud to be part of this journey," says Sectra Benelux Account Manager Digital Pathology, Jeroen van Laarhoven.
  • Sectra's digital pathology solution will be integrated with the laboratory information systems (LIS) used at the different locations.
  • The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise.

Ology Bioservices Named 2020 Company Of The Year By BioFlorida

Retrieved on: 
Friday, October 30, 2020

Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today the company was named the 2020 David J. Gury Company of the Year by BioFlorida.

Key Points: 
  • Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today the company was named the 2020 David J. Gury Company of the Year by BioFlorida.
  • BioFlorida distributes the award annually to a company that has achieved significant milestones and has contributed to the growth of Floridas life science industry.
  • We are honored to be named the 2020 BioFlorida Company of the Year, said Peter H. Khoury, Ph.D., President and CEO of Ology Bio.
  • We're excited to recognize Ology Bioservices as the BioFlorida Company of the Year and celebrate their growth and efforts towards manufacturing vaccines, monoclonal antibodies, viruses and nucleic acids for the U.S. government and commercial clients," said Nancy K. Bryan, President and CEO of BioFlorida.

ABEC Supporting Ology Bioservices COVID-19 Therapeutic Manufacturing Programs

Retrieved on: 
Wednesday, October 21, 2020

ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is delivering process systems to Ology Bioservices Inc. (Ology Bio) to support their production of critical vaccines and therapeutics for COVID-19.

Key Points: 
  • ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is delivering process systems to Ology Bioservices Inc. (Ology Bio) to support their production of critical vaccines and therapeutics for COVID-19.
  • ABEC is providing these systems to Ology Bioservices Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) facility in Alachua, Florida.
  • As a full-service biologics contract development and manufacturing organization (CDMO), Ology Bio selected ABEC for their ability to deliver customized bioprocess systems for solutions preparation and filtration applications on a fast-track schedule.
  • Complete in-house capabilities and significant global capacity for system and CSR single-use disposable container (DC) manufacturing enable ABEC to rapidly respond to the needs of biopharmaceutical industry leaders, such as Ology.

U.S. Army Contracting Command Awards Ology Bioservices Contract to Reserve Production Capacity in Support of Operation Warp Speed

Retrieved on: 
Wednesday, August 26, 2020

Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland.

Key Points: 
  • Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland.
  • The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of award.
  • In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and therapeutics for COVID-19.
  • This work is in support of the Operation Warp Speed response to the ongoing pandemic.

Ology Bioservices Wins Three Department of Defense Awards Totaling More Than $16 Million

Retrieved on: 
Tuesday, July 7, 2020

In the first program, valued at $8.5 million, Ology Bioservices will manufacture a conjugated vaccine candidate comprising the conserved protein from the bacterium Burkholderia pseudomallei and the adjuvant CPS-CRM-197.

Key Points: 
  • In the first program, valued at $8.5 million, Ology Bioservices will manufacture a conjugated vaccine candidate comprising the conserved protein from the bacterium Burkholderia pseudomallei and the adjuvant CPS-CRM-197.
  • In the second program, valued at $4.6 million, Ology Bioservices will manufacture outer membrane vesicles from Burkholderia mallei as a potential vaccine against the bacterial disease glanders.
  • In the third program, valued at $3.2 million, Ology Bioservices will manufacture a DNA vaccine against Venezuelan equine encephalitis to support a Phase 1 clinical trial.
  • We are pleased to be working with DTRA on these important programs, said Peter H. Khoury, President and CEO at Ology Bioservices.

Department of Defense Awards Ology Bioservices Contract to Advance Anti-Botulinum Neurotoxin Monoclonal Antibodies

Retrieved on: 
Thursday, June 25, 2020

In this program, Ology Bioservices will execute a randomized, double-blinded Phase 1 dose-escalation clinical trial of a cocktail of mAb against botulinum neurotoxin serotypes A and B.

Key Points: 
  • In this program, Ology Bioservices will execute a randomized, double-blinded Phase 1 dose-escalation clinical trial of a cocktail of mAb against botulinum neurotoxin serotypes A and B.
  • Ology Bioservices successfully transferred the technology and manufactured this candidate therapeutic for the DOD under a previous contract awarded in 2017.
  • This contract is an important milestone for both Ology Bioservices and the DOD, said Peter H. Khoury, Ph.D., President and Chief Executive Officer of Ology Bioservices.
  • Monoclonal antibodies represent an important, innovative option in medical countermeasure development, allowing the DOD to more effectively layer CBRN defense.

DGAP-News: JUST - EVOTEC BIOLOGICS TO COLLABORATE WITH OLOGY BIOSERVICES ON ANTIBODIES AGAINST CORONAVIRUS

Retrieved on: 
Thursday, April 30, 2020

Hamburg, Germany, 30 April 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its Seattle-based subsidiary Just - Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. ("Ology Bio") for the evaluation and analytical characterisation of antibodies against SARS-CoV-2.

Key Points: 
  • Hamburg, Germany, 30 April 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its Seattle-based subsidiary Just - Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. ("Ology Bio") for the evaluation and analytical characterisation of antibodies against SARS-CoV-2.
  • Just - Evotec Biologics' Abacus(TM) and analytical toolsets will help to filter these antibodies into a smaller set with predicted desirable characteristics for manufacturing and long term storage.
  • Dr Craig Johnstone, Chief Operating Officer of Evotec, comments: "Antibodies generated from convalescing patients do not necessarily translate into stable, manufacturable biotherapeutics.
  • Just - Evotec Biologics wholly owned by Evotec SE is a unique platform company that integrates the design, engineering, development, and manufacture of biologics.